Merit Med Sys (MMSI) Stock News

Merit Medical Systems (NASDAQ: MMSI) has appointed Martha Aronson as its new President and CEO, effective October 3, 2025. Founder Fred Lampropoulos will transition from his current role as President and CEO to continue serving as Chairman of the Board. Aronson brings extensive healthcare experience, having managed global businesses worth $500M-$1B at companies including Ecolab and Hill-Rom.

Additionally, Merit announced preliminary Q2 2025 revenue of $380-384 million, representing a 12-14% increase year-over-year. On a constant currency basis, revenue grew 11-13%. The company will release complete Q2 2025 financial results on July 30, 2025.

Merit Medical Systems (NASDAQ: MMSI), a leading healthcare technology manufacturer, has scheduled its second quarter 2025 financial results announcement for July 30, 2025, after market close. The company will host an investor conference call the same day at 5:00 p.m. Eastern Time.

Founded in 1987, Merit Medical specializes in proprietary medical devices for interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. The company maintains a global presence with over 800 sales and clinical support professionals and approximately 7,300 employees worldwide.

Merit Medical Systems (NASDAQ: MMSI) has acquired Biolife Delaware for approximately $120 million in cash and assumed liabilities. Biolife's StatSeal® and WoundSeal® hemostatic products address a $350M global market opportunity and are expected to add $18 million in revenue annually starting in FY2026. The acquisition is projected to contribute $10-11 million in revenue for the remainder of 2025. While slightly dilutive to 2025 non-GAAP profitability, the deal is expected to be accretive to non-GAAP margins in 2025 and earnings in 2026. Merit has updated its 2025 guidance, now expecting net sales of $1.480-$1.501 billion (9-11% growth) and non-GAAP EPS of $3.28-$3.41.

Merit Medical Systems (NASDAQ: MMSI) has received Health Canada approval for its WRAPSODY Cell-Impermeable Endoprosthesis (CIE), a device designed to treat vascular access stenosis in hemodialysis patients. The device features a unique tri-layer design with superior clinical outcomes demonstrated in the WAVE trial. At 12 months, WRAPSODY showed significantly higher target lesion primary patency (70.1% vs 41.6%) and access circuit primary patency (58.1% vs 34.4%) compared to standard angioplasty. The device, which received FDA approval in December 2024 and CE Mark for European use, will be immediately commercialized throughout Canada from Merit's Toronto distribution center. The innovative design includes an expandable nitinol stent frame, a cell-impermeable middle layer, and a novel inner layer to reduce complications.

Merit Medical Systems (NASDAQ: MMSI) has announced 12-month efficacy results for its WRAPSODY Cell-Impermeable Endoprosthesis (CIE) device from the single-arm arteriovenous graft (AVG) cohort of the WAVE trial. The study included 112 patients with AVG treated with WRAPSODY CIE.

Key findings include:

• 6-month target lesion primary patency (TLPP) of 81.4%, exceeding the performance goal of 60% by 21.4 percentage points
• 12-month TLPP of 60.2%
• Access circuit primary patency (ACPP) at 6 and 12 months were 69.2% and 36.2% respectively
• 95.4% of patients were free from adverse events, surpassing the safety goal of 89.0%

The WRAPSODY CIE is currently available in Brazil, the European Union, and is approved for commercial distribution in the United States.

Merit Medical Systems (MMSI) reported strong Q1 2025 financial results with revenue reaching $355.4 million, up 9.8% year-over-year. The company demonstrated solid performance with constant currency revenue growth of 10.9% and organic growth of 6.0%.

Key financial metrics include GAAP operating margin of 11.5% (up from 11.1%), non-GAAP operating margin of 19.3% (up from 17.0%), and GAAP EPS of $0.49 (up 2.0%). Non-GAAP EPS increased 14.8% to $0.86.

The company maintained its 2025 revenue guidance of $1.470-$1.490 billion but updated its non-GAAP EPS guidance to $3.29-$3.42, reflecting strong Q1 results offset by impacts from recent trade policies. As of March 31, 2025, Merit had cash and cash equivalents of $395.5 million and total debt of $747.5 million.

Merit Medical Systems (NASDAQ: MMSI) has announced the US commercial launch of its Ventrax™ Delivery System, the latest addition to its electrophysiology and cardiac rhythm management portfolio. The system is designed to facilitate ablation procedures for treating ventricular tachycardia (VT), a condition contributing to approximately 75% of sudden cardiac deaths in the US.

The Ventrax system features a 95-cm sheath for targeted access, ultralow-profile transition between sheath and pigtail-dilator, and an angled tip to enhance ablation catheter reach. It provides retrograde aortic access, offering improved access to certain ventricle areas compared to traditional methods.

Key medical experts from Duke Health, including Dr. Albert Sun and Dr. Jason Koontz, contributed to the system's development. The device addresses a growing need in VT ablation procedures, which represent one of the fastest-growing areas in electrophysiology.

Merit Medical Systems (NASDAQ: MMSI) has announced it will release its Q1 2025 financial results on April 24, 2025, after market close. The company will host an investor conference call the same day at 5:00 p.m. Eastern time.

Founded in 1987, Merit Medical Systems is a global manufacturer and marketer of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, with focus on cardiology, radiology, oncology, critical care, and endoscopy. The company maintains a global presence with over 800 sales and clinical support professionals and approximately 7,300 employees worldwide.

Merit Medical Systems (NASDAQ: MMSI) announced that the American Society for Gastrointestinal Endoscopy (ASGE) has updated its clinical guidelines to include Transoral Incisionless Fundoplication (TIF 2.0) and cTIF procedures as evidence-based approaches for managing GERD.

The company's EsophyX Z+ Device is designed for these procedures, which help restore anatomy and reconstruct the gastroesophageal valve. A recent multicenter study showed impressive results with a 94% clinical success rate and significant improvements in patient satisfaction from 8% to 79%.

GERD, affecting approximately 20% of Americans, occurs when stomach acid flows into the esophagus. The updated ASGE guidelines suggest TIF for patients with small hiatal hernias (≤2 cm) and cTIF or surgical therapy for those with larger hernias (>2 cm), based on multidisciplinary review.